𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model

✍ Scribed by Cornelis J. De Groot; Jenny A. Cadée; Jan-Willem Koten; Wim E. Hennink; Willem Den Otter

Publisher
John Wiley and Sons
Year
2001
Tongue
French
Weight
669 KB
Volume
98
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Interleukin‐2 (IL‐2) is a highly effective anticancer drug if it is applied locally for 5 consecutive days. In most cases this requires 5 invasive treatments, which is not usually acceptable for either the patient or the clinician. For this reason we have developed dextran‐based hydrogels from which the required amount of encapsulated IL‐2 (1–4 × 10^6^ IU of IL‐2) is gradually released during 5–10 days. Initially IL‐2‐containing macroscopic cylinder‐shaped gels (implants), and later IL‐2‐containing injectable microspheres, were developed. These preparations were characterized in vitro, and the therapeutic activity was tested in DBA/2 mice with SL2 lymphosarcoma. The therapy was given to mice with a large and extensively metastasized tumor load (at least 5% of the body weight). If 1–4 × 10^6^ IU of IL‐2 was slowly released from the hydrogels over a period of 5–10 days, the therapeutic effects were very good and comparable to the effects of free IL‐2 injections for 5 consecutive days. In conclusion, dextran‐based hydrogels are promising systems for the controlled release of IL‐2. © 2001 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Therapeutic efficacy of once-daily oral
Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer
✍ Hiroshi Kobayashi; Tatsuo Yagyu; Kiyokazu Inagaki; Toshiharu Kondo; Mika Suzuki; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB

## Abstract ## BACKGROUND Bikunin, a Kunitz‐type protease inhibitor, specifically inhibits tumor invasion and metastasis. ## METHODS The authors initially evaluated the therapeutic efficacy of once‐daily oral administration of different doses of bikunin against human ovarian carcinoma HRA cells

Dephosphorylation of p-ERK1/2 in relatio
Dephosphorylation of p-ERK1/2 in relation to tumor remission after HER-2 and Raf1 blocking therapy in a conditional mouse tumor model
✍ Carolin K. Hausherr; Ilka B. Schiffer; Susanne Gebhard; Andreas Banić; Berno Tan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 1 views

## Abstract Several studies have shown that HER‐2/neu (erbB‐2) blocking therapy strategies can cause tumor remission. However, the responsible molecular mechanisms are not yet known. Both ERK1/2 and Akt/PKB are critical for HER‐2‐mediated signal transduction. Therefore, we used a mouse tumor model